Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD25-depleted donor lymphocytes
- Development stage
- Phase 1
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
CD25-depleted donor lymphocytes is an investigational allogeneic cell therapy consisting of peripheral blood mononuclear cells (PBMCs) derived from an HLA-matched donor. The product is selectively depleted of CD4+CD25hiFoxp3+ regulatory T cells (Tregs) using antibody-conjugated magnetic beads, specifically via the CliniMACS CD25 system. By removing these immunosuppressive Tregs, the therapy aims to enhance the proliferation of effector T cells and induce a potent graft-versus-tumor (GVT) immune response in patients who have relapsed after allogeneic hematopoietic stem cell transplantation (HSCT). It has been primarily investigated by the Dana-Farber Cancer Institute for the treatment of relapsed hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
- Other names
- CD25/Treg-depleted donor lymphocytesallogeneic CD25/Treg-depleted donor lymphocytesallogeneic Treg-depleted donor lymphocytesCD25+ Regulatory T CELL-Depleted Donor Lymphocyte Infusion
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on CD25-depleted donor lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD25-depleted donor lymphocytes.